TOPCF - Iridex: A Clear Vision For Success

• IRIX recently blew away analyst estimates for Q1 sales, with multiple tailwinds for continued success in 2021 and beyond.
• The company’s recent partnership with Japanese giant, Topcon, validates IRIX’s technology and takes the threat of a dilutive capital raise off the table.
• Flush with cash, IRIX can now properly focus on its two key markets of retina and glaucoma, and the different sales approach needed for each of these markets.
• The glaucoma market is particularly lucrative, and IRIX offers arguably the most efficient treatment for this disease.
• I will show why I believe IRIX shares should currently be worth 50% more than the current market price, with plenty of upside beyond that as the company scales glaucoma sales globally.

For further details see: